Sandoz

If 100 CHF had been invested in Sandoz a year ago (closing price 48.91 CHF), the investor would now hold 2.045 shares worth 150.07 CHF at a price of 73.40 CHF on 18.08.2026. That corresponds to a value increase of 50.07 percent. The Sandoz share was first listed on 04.10.2023 at a price of 24.00 CHF; stock splits and dividends are not included in the calculation. » Más en finanzen.net

Sandoz agreed a comprehensive partnership with Shanghai Henlius Biotech with a potential total value of up to $322 million and near-term payments of up to $100.5 million in 2026. The cooperation covers up to 10 biosimilar active substances; Sandoz will receive global commercialization rights outside China, while Henlius will take on development and manufacturing. The first tranche confirmed three products targeting evolocumab, belimumab and cetuximab, plus an option for recombinant hyaluronidase. The announcement pushed the share to a daily high of 75.56 CHF and a new 52-week high, supported by an already strong business momentum in H1 2026. » Más en de.investing.com

According to the agreement with Sandoz, Shanghai Henlius Biotech granted exclusive rights for approval and commercialization of up to ten product candidates outside China, including indications in oncology, autoimmune diseases and ophthalmology. The partnership is intended to secure Henlius’ international expansion through Sandoz’s commercial infrastructure and support its revenue-diversification goal. The stock then rose 1.2% to HK$68.1 amid a broader upswing in the Hong Kong market. » Más en de.investing.com